Allergan migraine portfolio grows with Merck CGRP antagonists

Allergan will have four migraine therapies in its portfolio after licensing two oral CGRP antagonists for treatment and prevention of the debilitating headaches from Merck & Co, joining a field crowded with injectable CGRP-targeting biologics.

Allergan will have four migraine therapies in its portfolio after licensing two oral CGRP antagonists for treatment and prevention of the debilitating headaches from Merck & Co, joining a field crowded with injectable CGRP-targeting biologics.

The companies made sure to note in a 7 July joint announcement that MK-1602 and MK-8031 belong to a different...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category